Compare ARK Genomic Revolution ETF (ARKG) vs Brown-Forman Corporation Class B (BF.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Brown-Forman Corporation Class B — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Brown-Forman Corporation Class B trades at $26.14. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Brown-Forman Corporation Class B nearer its low. Which is the better fit depends on your goals.
| ARKG | BF.B | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $31.26 |
52-Week Low | $23.09 | $22.80 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
BF.B trades at $26.17, up 3.77% today, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings show three beats out of four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst consensus is mixed, with 25% buy, 50% hold, and 25% sell ratings, reflecting cautious optimism amid weak valuation ratio data.
The stock faces headwinds from bearish technical trends and incomplete fundamental metrics, but consistent earnings beats provide a positive catalyst. Risks include market volatility and lack of recent news, while institutional sentiment remains divided. Upside depends on future financial disclosures confirming profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →
